Liquidia Corporation, a biopharmaceutical company focused on respiratory and vascular diseases, will announce its second quarter 2026 financial results on August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Liquidia is known for its innovative therapies including YUTREPIA, approved for pulmonary arterial hypertension, and is developing new treatments like L606. Investors and interested parties can access the webcast on Liquidia’s website, with a rebroadcast available for one year.
Greg Abel highlighted that every one-point increase in BNSF's profit margin translates to about $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational efficiency has on Berkshire's over...
ArbitrumDAO members passed an off-chain vote supporting a proposal to allocate 100 million ARB tokens as incentives for the Global Dollar (USDG) stablecoin. The vote saw 94.7% approval from participating members, representing 68% of total ARB tokens....
Greg Abel highlighted that each percentage point increase in BNSF's profit margin translates to approximately $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact of BNSF's operational efficiency on Ber...
Enova reported strong Q3 results with 33% adjusted EPS growth and 26% revenue growth, supported by a focus on business loans and a lower net charge-off ratio. Despite the failed acquisition of Grasshopper Bank, management plans to accelerate share bu...
A Bitcoin transaction on October 17 placed a 100-byte plaintext message in block 971,914 using an OP_RETURN output, which allows data to be recorded but not spent. This message, paying a fee of 253 satoshis, included text about quartz clocks and the ...
